RBC Capital raised the firm’s price target on Medtronic (MDT) to $118 from $111 and keeps an Outperform rating on the shares. The company delivered a 1.0% beat on sales and 3.8% on EPS in Q2, driven by accelerating cardiovascular performance, the analyst tells investors in a research note. RBC further cites Medtronic expecting similar growth in Q3 and to exit the FY at 6%, noting that its thesis of growth acceleration is playing out.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target raised to $102 from $95 at UBS
- Medtronic price target raised to $109 from $103 at Baird
- Medtronic price target raised to $114 from $100 at Wells Fargo
- Cautious Hold Rating on Medtronic Amid Mixed Segment Performance and Uncertain Growth Prospects
- Medtronic price target raised to $111 from $98 at Bernstein